In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Traversa Therapeutics Inc.

www.traversathera.com

Latest From Traversa Therapeutics Inc.

venBio Rings In 2013 With Two Company Launches

New venture firm venBio, which closed its inaugural $200 million fund in 2010, has begun the new year by unveiling two start ups with very different business propositions.

BioPharmaceutical United States

The A-List: 2008's Trend Shaping Series A Financings

Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2008 were down from last year's highs; in devices, small and regional VCs have filled the void left by brand-name investors.
BioPharmaceutical Medical Device

Traversa Therapeutics Inc

Traversa aims to solve a fundamental problem: the adequate delivery of short interfering RNA molecules to a wide range of cell types via a non-cytoxic mechanism.
BioPharmaceutical Business Strategies

Glioblastoma Start-Ups Get Specific

For start-ups developing novel and risky medicines to treat glioblastoma, a rare, invasive form of brain cancer, the Pfizer/Avant deal was a watershed moment: It signaled the vigorous interest of a pharmaceutical behemoth in a disease where patients number in just the tens of thousands. The positive effects are likely to be felt in executive suites of biotechs developing therapeutics for this grievous disease.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Traversa Therapeutics Inc.
  • Senior Management
  • Hans A Petersen, Pres. & CEO
    Curt Bradshaw, PhD, VP, R&D
  • Contact Info
  • Traversa Therapeutics Inc.
    Phone: (858) 454-8400
    505 Coast Blvd. S
    La Jolla, CA 92037-4613
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register